Article Information
History
- August 21, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Afrah Khairallah1,
- Zesuliwe Jule1,
- Alice Piller1,
- Mallory Bernstein1,
- Kajal Reedoy1,
- Yashica Ganga1,
- Bernadett I. Gosnell2,
- Farina Karim1,
- Yunus Moosa2,
- Thumbi Ndung’u1,3,4,5,
- Khadija Khan1 and
- Alex Sigal1,6,*
- 1Africa Health Research Institute and University of KwaZulu-Natal, Durban, South Africa
- 2Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa
- 3HIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South Africa
- 4Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA
- 5Division of Infection and Immunity, University College London, London, UK
- 6The Lautenberg Center for Immunology and Cancer Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
- ↵*Corresponding author; email: alexander.sigal{at}gmail.com
Posted August 21, 2024.
Severe disease is not essential for a high neutralizing antibody response post-SARS-CoV-2 infection
